支持性寡核苷酸治疗（SOT）作为癌症的一种替代治疗选择：一项初步研究。
Supportive Oligonucleotide Therapy (SOT) as an Alternative Treatment Option in Cancer: A Preliminary Study.
机构信息
Research Genetic Cancer Centre International GmbH, Zug, Switzerland;
Research Genetic Cancer Centre S.A., Industrial Area of Florina, Florina, Greece.
出版信息
In Vivo. 2022 Mar-Apr;36(2):898-906. doi: 10.21873/invivo.12779.
BACKGROUND/AIM: An early evaluation concerning the effectiveness of supportive oligonucleotide therapy (SOT) in cancer as a monotherapy and in combination with other types of treatment.
PATIENTS AND METHODS
This study evaluated the clinical condition and performance status (Karnofsky-Index) of 95 patients, post-SOT administration. Furthermore, circulating tumor cells (CTCs) from 47 patients' pre- and post-SOT administration were measured and analyzed by repeated-measures ANOVA.
RESULTS
Improvement of the clinical condition was observed in all patients who used SOT (77.89%), SOT in combination with other therapy (69.77%) and SOT as a monotherapy or no information was given concerning another therapy (84.31%). Positive results for Karnofsky-Index were also observed in 71.58%, 61.36%, and 80.39%, respectively. Finally, statistically significant reductions in CTCs were observed for both SOT as a monotherapy and SOT as an adjunctive therapy.
CONCLUSION
The preliminary results indicate that SOT therapy can be used both as monotherapy as well as in combination with other therapies for cancer.
背景/目的：评估支持性寡核苷酸疗法（SOT）作为单一疗法和与其他类型治疗联合应用于癌症的疗效的早期评估。
患者和方法
本研究评估了 95 例患者在 SOT 给药后的临床状况和表现状态（卡诺夫斯基指数）。此外，通过重复测量方差分析对 47 例患者 SOT 给药前后的循环肿瘤细胞（CTC）进行了测量和分析。
结果
所有使用 SOT（77.89%）、SOT 联合其他治疗（69.77%）以及 SOT 作为单一疗法或未提供其他治疗信息的患者（84.31%）的临床状况均得到改善。卡诺夫斯基指数的阳性结果也分别为 71.58%、61.36%和 80.39%。最后，SOT 作为单一疗法和辅助疗法均观察到 CTC 数量的统计学显著减少。
结论
初步结果表明，SOT 疗法可作为单一疗法以及与其他癌症治疗联合应用。
Zotero 插件